NICE TA534: for treating moderate to severe atopic dermatitis. (Decision date - Sep 2018).
Dupiliumab has been awarded an EAMS status for severe
atopic dermatitis.
NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation. (Decision date - February 2022).
Use in children 6 to 11 years old as add-on maintenance treatment for
severe asthma with type 2 inflammation. (NHSE commissioned.) (Decision date - October 2022).
DO NOT PRESCRIBE (DNP):
NICE TA648: for treating chronic rhinosinusitis with nasal polyps. (Terminated appraisal). (Decision date - October 2020).
NICE TA938:for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). (Decision date - January 2024)
NICE TA955: for treating moderate to severe prurigo nodularis. Not recommended. (Decision date - April 2024)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
